{"filings":[{"id":746518,"accession_number":"0001140361-26-023312","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-05-29T20:05:27+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nu Skin shareholders approve amended 2024 omnibus incentive plan with 2.85M share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share reserve by 2,850,000 to 4,859,919 shares.","Plan termination date extended to May 28, 2036, ten years from effective date of May 28, 2026.","Voting results: 24,185,333 for, 10,177,825 against, 40,483 abstain, 5,430,258 broker non-votes.","All nine director nominees elected; advisory say-on-pay approved; PricewaterhouseCoopers ratified as auditor for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90643,"accession_number":"0001140361-26-020028","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin EVP & Chief Product Officer Hatchett resigns effective May 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven K. Hatchett resigns as EVP and Chief Product Officer due to family health circumstances.","Hatchett will stay as a strategic product advisor with $147,478 annual salary.","No replacement for Chief Product Officer announced.","Effective date of resignation is May 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90642,"accession_number":"0001140361-26-019586","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $320.6M (-12% YoY), EPS $0.04; guides FY rev $1.35-1.50B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $320.6M, -12% YoY (1.1% FX tailwind); GAAP EPS $0.04, adjusted EPS $0.14 vs $0.23 prior.","Customers 669,535 (-14%), paid affiliates 120,850 (-8%), sales leaders 26,915 (-13%).","Q2 rev guidance $330-360M (-15% to -7%); EPS $0.15-0.25. FY rev $1.35-1.50B; EPS $0.70-1.10.","Returned $8M to shareholders: $2.9M dividends, $5.0M buybacks; $137.3M remaining in authorization.","Refinanced debt to extend liquidity; investing in Prysm iO platform and India launch expected late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":320608000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100338,"accession_number":"0001140361-26-011757","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nu Skin closes $175M term loan and $75M revolver in credit refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$175M term loan fully drawn to repay existing credit agreement; $75M revolving facility also available.","Five-year maturity; interest is Term SOFR plus initial spread of 1.75% or base rate plus 0.75%.","Covenants require consolidated leverage ratio ≤2.25x and interest coverage ratio ≥3.00x.","Obligations guaranteed by material domestic subsidiaries and secured by capital stock of those subsidiaries.","Bank of America serves as administrative agent; HSBC, KeyBank, Zions, Bangkok Bank, Citibank also lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100337,"accession_number":"0001140361-26-010559","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nu Skin CFO James Thomas resigns; Chelsea Lantz named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Thomas resigned as EVP and CFO effective March 17, 2026, to pursue an outside opportunity.","Chelsea Lantz, previously VP and Corporate Controller, appointed Interim CFO effective March 18.","Lantz will earn $300,000 annual salary, 35% target bonus, plus $25,000 quarterly stipend.","Board initiated search for permanent CFO, considering both internal and external candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100336,"accession_number":"0001140361-26-008469","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nu Skin appoints Chayce Clark as COO; retains CLO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Clark appointed EVP, COO & CLO effective March 5, 2026; will oversee global ops, sales, product innovation, tech, brand, and legal.","Base salary $650k, target bonus 75% of salary; 2026 equity award $2,362,500 (50% RSUs, 50% PRSUs).","RSUs vest 25% annually 2027–2030; PRSUs vest in three tranches based on 2026, 2027, 2028 EPS.","Clark joined Nu Skin in 2015; previously EVP & General Counsel. No family relationships or reportable transactions.","CEO cites Prysm iO platform rollout and India expansion as key growth opportunities under Clark's leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100335,"accession_number":"0001140361-26-005018","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 revenue $370.3M (-16.9% YoY); FY2025 EPS $3.18, adj. $1.27; Q1 2026 outlook weak","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $370.3M, down 16.9% YoY; EPS $0.29 vs $(0.73) prior year.","FY2025 revenue $1.49B (-14.3%); EPS $3.18 (incl. Mavely gain), adjusted EPS $1.27 vs $0.84 prior.","Q1 2026 guidance: revenue $320-340M, EPS $0.10-0.20; full year 2026 revenue $1.35-1.50B, EPS $0.80-1.20.","Customers 748,796 (-10%), paid affiliates 129,311 (-11%), sales leaders 30,045 (-19%).","Company anticipates return to revenue growth by year-end 2026; 20,000+ Prysm iO devices deployed."],"consensus_eps_estimate":null,"consensus_eps_actual":3.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1485159000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116673,"accession_number":"0001140361-25-040790","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q3 revenue $364.2M (-15.3% YoY); EPS $0.34 in line with guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $364.2M, down 15.3% YoY (down 11.5% ex-Mavely); EPS $0.34 vs $0.17 prior year.","Customers 746,256 (-10%), Paid Affiliates 130,096 (-13%), Sales Leaders 31,150 (-19% YoY).","Gross margin improved to 70.5% from 70.1%; Nu Skin business gross margin 77.7% vs 76.5%.","Q4 2025 revenue outlook $365-400M, EPS $0.25-0.35; FY 2025 revenue $1.48-1.51B, EPS $3.15-3.25.","Preparing for limited Prysm iO launch and pre-market opening in India; paid $3.0M dividends, $5.0M buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":2.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1114839000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133118,"accession_number":"0001140361-25-029613","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 EPS $0.43 beats guidance; raises FY EPS outlook to $3.05-$3.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $386.1M, down 12% YoY; EPS $0.43 (adj. $0.21) vs ($2.38) prior year.","Operating margin 8.0% (vs (28.6)%); positive net cash position achieved for first time in >4 years.","Customers 771K (-14%), Sales Leaders 29.6K (-23%), Paid Affiliates 130.8K (-16%).","Rhyz Manufacturing segment +17% YoY; Latin America revenue +107% YoY.","FY 2025 guidance narrowed: rev $1.48-$1.55B; EPS raised to $3.05-$3.25 (adj. $1.15-$1.35)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":750628000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149718,"accession_number":"0001140361-25-020939","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nu Skin stockholders approve amended 2024 incentive plan with 790k additional shares and extension to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share authorization by 790,000 shares (30,535,949 for, 1,899,631 against).","Plan termination date extended to May 29, 2035; clarifies performance cash awards not subject to minimum vesting.","All nine director nominees elected; advisory vote on executive compensation passed with ~93% support (30,210,716 for, 825,311 against).","Ratification of PricewaterhouseCoopers as independent auditor for 2025 passed with 38,374,875 for versus 492,904 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149717,"accession_number":"0001140361-25-017961","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $364.5M at high end of guidance; adj EPS $0.23 excl. Mavely gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $364.5M (-12.7% YoY, ~3% FX headwind); GAAP EPS $2.14 includes $176.2M Mavely gain; adjusted EPS $0.23.","Customers 776,712 (-11%), paid affiliates 131,518 (-15%), sales leaders 31,036 (-20%).","Reduced debt by $155M, lowest in 10+ years; returned $8M to shareholders ($3M dividends, $5M buybacks).","Q2 outlook: rev $355-390M, EPS $0.20-0.30; FY2025 rev $1.48-1.62B, adj EPS $0.90-1.30.","New product Prysm iO intelligent wellness device preview in H2 2025; India market pre-opening Q4 2025, launch mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":364490000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168750,"accession_number":"0001140361-25-007278","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin director Zheqing (Simon) Shen will not stand for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shen informed the company on March 5, 2025, of his decision due to other professional commitments.","The board thanked Shen for his contributions and years of service.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168749,"accession_number":"0001140361-25-004320","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 revenue $445.6M, beat guidance; full-year 2025 revenue outlook $1.48-1.62B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $(0.73); adjusted EPS $0.38 vs $0.37 prior year; revenue down 8.8% YoY.","Full-year 2024 revenue $1.73B (-12%); GAAP EPS $(2.95), adjusted $0.84 vs $1.85.","Rhyz segment Q4 revenue $83.1M (+27.7%); CEO cites improving trends but China/S Korea headwinds.","Q1 2025 guidance: revenue $345-365M, EPS $2.65-2.75 (incl Mavely gain) or $0.10-0.20 ex gain.","Full-year 2025 revenue outlook $1.48-1.62B; adjusted EPS ex-Mavely gain $0.90-1.30."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1732084000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168748,"accession_number":"0001140361-25-000867","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 prelim revenue at high end of guidance; closed Mavely deal for $250M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2024 preliminary revenue at high end of company's guidance range.","Recently closed strategic transaction of Mavely for $250 million.","Full Q4 and FY2024 results to be announced on Feb. 13, 2025.","CEO Ryan Napierski and CFO James Thomas to present at ICR Conference on Jan. 14."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1732084000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168747,"accession_number":"0001140361-25-000113","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Nu Skin sells Mavely to Later for $250M; expects ~$207M cash, $10M stock after distributions","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $230M cash plus $20M in Purchaser common stock; closed January 2, 2025.","Nu Skin expects to retain ~$207M cash and $10M stock after payments to other Mavely equity holders.","Transaction generated ~5x return on Nu Skin's cumulative investment in Mavely since 2021 acquisition.","Proceeds to be used for debt reduction, innovation, and share repurchases under existing program.","Mavely to continue providing technology and social commerce capabilities to Nu Skin's affiliate marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185877,"accession_number":"0001140361-24-045667","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q3 revenue $430.1M (-13.8% YoY), EPS $0.17; guides lower Q4/FY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $430.1M (-13.8% YoY); customers 831,768 (-15%), paid affiliates 149,264 (-20%).","GAAP EPS $0.17 vs $(0.74); adjusted EPS $0.56 excluding prior-year inventory write-off.","Rhyz segment revenue $73.1M, up 20.9% YoY, partially offsetting Nu Skin core weakness.","Q4 guidance: rev $410-445M, non-GAAP EPS $0.19-0.29; FY24 rev $1.70-1.73B, non-GAAP EPS $0.65-0.75.","Cost-efficiency program: saved $15M in Q3, on track for $45-65M in 2024; cash from ops $31.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":1286532000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185876,"accession_number":"0001140361-24-045001","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nu Skin adopts amended bylaws updating stockholder proposal and nomination procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Sixth Amended and Restated Bylaws effective Oct 31, 2024.","Clarifies nominee limit equals number of directors to be elected at meeting.","Requires stockholder nominees to submit D&O questionnaire and disclosure of compensation arrangements.","Permits company to request additional info on independence, background, and experience of nominees.","Updates procedural requirements for special meetings and information supplementation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202439,"accession_number":"0001140361-24-040955","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin appoints Mark A. Zorko to board; Audit and Nominating committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark A. Zorko appointed as director effective September 10, 2024, increasing board to nine members.","Zorko will serve on Audit Committee and Nominating and Corporate Governance Committee.","Cash retainer and annual equity award pro-rated to 75% due to mid-year appointment.","Expected to enter standard indemnification agreement; no related-party transactions reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202438,"accession_number":"0001140361-24-036406","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 revenue $439M, GAAP EPS $(2.38) on $141M impairment charge; guides FY24 revenue $1.73-1.81B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $439.1M, down 12.2% YoY; FX headwind of 4.2% ($21.0M).","GAAP EPS $(2.38) vs $0.54 prior-year; adjusted EPS $0.21 excluding restructuring and impairment charges.","Recorded $141M non-cash goodwill and intangibles impairment charge due to stock price decline.","Rhyz segment revenue $67.8M (+32.3% YoY); core Nu Skin customers down 14% to 893,514.","Q3 2024 revenue guidance $430-$465M; FY2024 revenue narrowed to $1.73-$1.81B, adjusted EPS $0.75-$0.95."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":856387000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218572,"accession_number":"0001140361-24-029122","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nu Skin stockholders approve 2024 Omnibus Incentive Plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2024 Omnibus Incentive Plan, authorizing 1,219,919 new shares plus prior plan carryover.","All eight director nominees elected with over 35M votes for each; no significant opposition.","Advisory vote on executive compensation passed with 36.99M for vs 1.42M against.","Ratification of PricewaterhouseCoopers as independent auditor for 2024 passed with 41.57M for.","Plan effective June 5, 2024, expires June 5, 2034, replaces 2010 plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218571,"accession_number":"0001140361-24-024942","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $417.3M, down 13%; EPS $(0.01) GAAP; customer base shrinks 19%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $417.3M, down 13.3% YoY; foreign currency hit of $18.2M; Rhyz revenue up 57.5% to $62.5M.","GAAP EPS $(0.01); adjusted EPS $0.09 ex-restructuring vs $0.37 prior year; gross margin 70.5%.","Customers 875,261 (-19%); paid affiliates 154,171 (-30%); sales leaders 38,609 (-12%).","Q2 2024 guidance: revenue $420-455M, EPS $0.01-0.10 GAAP; 2024 full-year revenue $1.73-1.87B.","CEO cites macro headwinds; cost management supported earnings; India opening expected next year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":417306000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238470,"accession_number":"0001140361-24-013913","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Andrew Lipman to retire from Nu Skin board, will not seek re-election at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Lipman informed Nu Skin on March 15, 2024 of his decision to retire from the Board.","He will not stand for re-election at the 2024 Annual Meeting of Stockholders.","Company and Board extended gratitude for his years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238469,"accession_number":"0001140361-24-007981","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.","FY2023 revenue $1.97B (-12%); adj EPS $1.85 after inventory write-off charges.","FY2024 guidance: rev $1.73-1.87B, adj EPS $0.95-1.35; Q1 rev $400-435M, adj EPS $0.00-0.10.","Quarterly dividend set at $0.06/share; record Feb 26, payable Mar 6, 2024.","CSO Joseph Chang departs Mar 30; will transition to Scientific Advisory Board; role no longer executive."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1969131000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238468,"accession_number":"0001140361-24-005870","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nu Skin adopts amended bylaws aligning with Delaware law and updating stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended to align with current DGCL provisions and certificate of incorporation.","Updated advance notice deadlines and proxy solicitation rules for stockholder meetings.","Directors must submit irrevocable resignation to stand for re-election under majority voting policy.","Enhanced disclosure requirements for stockholder nominations and proposals.","Clarified advancement of expenses for former directors/officers with repayment undertaking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}